Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial
Annals of the Rheumatic Diseases · 2026-03 · 85 (3) · 566-574
DOI: 10.1016/j.ard.2025.07.008 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Annals of the Rheumatic Diseases, 2026-03. Verfasst von Marianne Uggen Rasmussen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark. Electronic address: marianne.uggen.rasmussen@regionh.dk. Hauptthemen laut MEDLINE: Fibromyalgia, Cannabidiol, Analgesics. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Oak Foundation, Copenhagen University Hospital, Arthritis Society.
Abstract (Originalsprache)
OBJECTIVES: Cannabidiol (CBD) is used to alleviate fibromyalgia pain despite limited evidence for efficacy. This study assessed the efficacy and safety of CBD vs placebo in patients with fibromyalgia, hypothesising that CBD would be superior to placebo in reducing pain. METHODS: In this single-centre, double-blind, randomised, placebo-controlled trial, patients diagnosed with fibromyalgia were recruited from a specialised outpatient clinic in Denmark. Eligible participants were randomised 1:1 and stratified by sex, defined as biological sex assigned at birth based on physical anatomy. Age (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark. Electronic address: marianne.uggen.rasmussen@regionh.dk.
- Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmar…
- Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; User Perspectives and Community-based Interventions, Department of Public Health, University of Southern Denmark, Odense, Denmark.
- Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark.
Förderung
- Oak Foundation
- Copenhagen University Hospital
- Arthritis Society
- Parker Institute for Cancer Immunotherapy
- Ministero dell'Università e della Ricerca
- Gentofte Hospital
- Region Hovedstaden
- Minister Erna Hamilton's Scholarship for Science and Art
Zitieren
APA
Rasmussen, M. U., Christensen, R., Wæhrens, E. E., Henriksen, M., Duhn, P. H., Bliddal, H., & Amris, K. (2026). Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial. Annals of the Rheumatic Diseases, 85(3), 566-574. https://doi.org/10.1016/j.ard.2025.07.008
Vancouver
Rasmussen MU, Christensen R, Wæhrens EE, Henriksen M, Duhn PH, Bliddal H, et al. Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial. Annals of the Rheumatic Diseases. 2026;85(3):566-574. doi:10.1016/j.ard.2025.07.008
BibTeX
@article{Rasmussen2026,
author = {Rasmussen, Marianne Uggen and Christensen, Robin and Wæhrens, Eva Ejlersen and Henriksen, Marius and Duhn, Pernille Hurup and Bliddal, Henning and Amris, Kirstine},
title = {Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
volume = {85},
number = {3},
pages = {566--574},
doi = {10.1016/j.ard.2025.07.008}
}
EUVIMED